A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors

Status

Suspended

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505322-34-00

Acronym

BGB-A317-A3055-101

Enrollment

Registered

2023-12-04

Start date

2024-01-08

Completion date

Unknown

Last updated

2025-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or metastatic solid tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026